GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Athenex Inc (OTCPK:ATNXQ) » Definitions » Earnings Power Value (EPV)

Athenex (Athenex) Earnings Power Value (EPV) : $-207.80 (As of Dec22)


View and export this data going back to 2017. Start your Free Trial

What is Athenex Earnings Power Value (EPV)?

As of Dec22, Athenex's earnings power value is $-207.80. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Athenex Earnings Power Value (EPV) Historical Data

The historical data trend for Athenex's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athenex Earnings Power Value (EPV) Chart

Athenex Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Earnings Power Value (EPV)
Get a 7-Day Free Trial - - -449.31 -415.34 -207.80

Athenex Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -415.34 -363.74 -300.18 -243.22 -207.80

Competitive Comparison of Athenex's Earnings Power Value (EPV)

For the Drug Manufacturers - Specialty & Generic subindustry, Athenex's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Athenex's Earnings Power Value (EPV) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Athenex's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Athenex's Earnings Power Value (EPV) falls into.



Athenex Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

Athenex's "Earning Power" Calculation:

Average of Last 20 Quarters Last Quarter
Revenue 107.1
DDA 3.4
Operating Margin % -148.43
SGA * 25% 16.0
Tax Rate % 0.10
Maintenance Capex 5.8
Cash and Cash Equivalents 31.5
Short-Term Debt 39.2
Long-Term Debt 3.1
Shares Outstanding (Diluted) 8.0

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = -148.43%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = $107.1 Mil, Average Operating Margin = -148.43%, Average Adjusted SGA = 16.0,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 107.1 * -148.43% +16.0 = $-142.929706345 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = 0.10%, and "Normalized" EBIT = $-142.929706345 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = -142.929706345 * ( 1 - 0.10% ) = $-142.78606199012 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 3.4 * 0.5 * 0.10% = $0.0017081985 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = -142.78606199012 + 0.0017081985 = $-142.78435379162 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
Athenex's Average Maintenance CAPEX = $5.8 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. Athenex's current cash and cash equivalent = $31.5 Mil.
Athenex's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 3.1 + 39.2 = $42.358 Mil.
Athenex's current Shares Outstanding (Diluted Average) = 8.0 Mil.

Athenex's Earnings Power Value (EPV) for Dec22 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( -142.78435379162 - 5.8)/ 9%+31.5-42.358 )/8.0
=-207.80

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( -207.79605378631-0.0152 )/-207.79605378631
= N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.


Athenex  (OTCPK:ATNXQ) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Athenex Earnings Power Value (EPV) Related Terms

Thank you for viewing the detailed overview of Athenex's Earnings Power Value (EPV) provided by GuruFocus.com. Please click on the following links to see related term pages.


Athenex (Athenex) Business Description

Traded in Other Exchanges
N/A
Address
1001 Main Street, Suite 600, Conventus Building, Buffalo, NY, USA, 14203
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.
Executives
Jinn Wu director 107 MORGAN LANE, PLAINSBORO NJ 08536
Lau Johnson Yiu Nam director, officer: CEO and Chairman of the Board
Joe Annoni officer: Chief Financial Officer C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Timothy Devere Cook officer: See Remarks C/O ATHENEX, INC., 1001 MAIN STREET,, SUITE 600, BUFFALO NY 14203
Daniel Lang officer: Pres Cell Therapy, VP Corp Dev C/O ATHENEX, INC. CONVENTUS BUILDING, 1001 MAIN ST. STE. 600, BUFFALO NY 14203
Jordan Kanfer director C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Rudolf Kwan director, officer: EVP, Chief Medical Officer C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Michael Smolinski officer: Chief Scientific Officer C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Steven J. Adams officer: Interim Chief Acct Officer C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Kim Campbell director 3300 HYLAND AVE, COSTA MESA CA 92626
William Wei Zuo officer: President, China 3040 POST OAK BLVD, SUITE 1110, HOUSTON TX 77056
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Manson Fok director C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Randoll Sze officer: Chief Financial Officer C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Stephanie A Davis director C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203

Athenex (Athenex) Headlines

From GuruFocus

Athenex to Participate in Truist Securities Cell Therapy Symposium

By GuruFocusNews GuruFocusNews 06-23-2022

Athenex Announces a Reverse Stock Split

By sperokesalga sperokesalga 02-14-2023

Athenex Announces Receipt of Positive Nasdaq Listing Determination

By Value_Insider Value_Insider 11-03-2022